Christie M. Ballantyne
Articles
-
2 weeks ago |
healio.com | Erik Swain |Christie M. Ballantyne
Topline data show efficacy, safety of novel oral PCSK9 inhibitor for LDL lowering• Topline results from two phase 3 trials of a novel oral PCSK9 inhibitor for treatment of HeFH and hyperlipidemia were positive. • Enlicitide decanoate met its primary endpoints in both trials. Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and those with hyperlipidemia vs. placebo and other lipid-lowering therapies, Merck reported.
-
Jan 17, 2025 |
healio.com | Scott Buzby |Richard Smith |Christie M. Ballantyne
The year in lipids: Progress in Lp(a) management and a blow to the ‘HDL hypothesis’• Topics included triglyceride and lipoprotein(a) management as well as another setback to the “HDL hypothesis.”In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention of major adverse CV events. At the Cardiometabolic Health Congress in October, Christie M.
-
Oct 17, 2024 |
healio.com | Scott Buzby |Erik Swain |Keith C. Ferdinand |Christie M. Ballantyne
You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Speakers highlighted recent regulatory moves in the areas of hypertension, lipids and diabetes.
-
Oct 16, 2024 |
healio.com | Scott Buzby |Katie Kalvaitis |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The Cardiometabolic Health Congress takes place Oct. 17-19 in Boston. The meeting will feature four main sessions with presentations that span the field of cardio-kidney-metabolic care and more.
-
Jun 7, 2024 |
healio.com | Erik Swain |Richard Smith |Christie M. Ballantyne
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Much of the cardiology field is focused on treating end-stage heart disease, but prevention is more important. The National Lipid Association (NLA) is prioritizing research and education on prevention of CVD.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →